ALKS to Enter Sleep Disorder Market With $2.1B Avadel Acquisition
Alkermes inks $2.1B deal to acquire Avadel, adding the latter's Lumryz and new growth potential to its portfolio.
Zacks·9d ago
More News
Best Momentum Stocks to Buy for Oct. 23
PARR, CMMB and GES made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on Oct. 23, 2025.
Zacks·9d ago
New Strong Buy Stocks for Oct. 23: MQ, GES and More
MQ, GES, TRV, CMMB and PARR have been added to the Zacks Rank #1 (Strong Buy) List on Oct. 23, 2025.
Zacks·9d ago
SNY's Efdoralprin Alfa Meets Key Endpoints in Rare Disease Study
Sanofi's efdoralprin alfa meets all key endpoints in a global phase II study, showing potential as a first restorative recombinant therapy for AATD.
Zacks·10d ago
Roche's Gazyva Secures FDA Nod for Label Expansion in Lupus Nephritis
RHHBY secures FDA approval to expand Gazyva's label for treating lupus nephritis, offering patients a faster and more convenient treatment option.
Zacks·11d ago
NVO's Rybelsus Gets FDA Nod to Reduce Heart Risk in Diabetes Patients
Novo Nordisk secures FDA approval for Rybelsus as the first oral GLP-1 therapy proven to cut major heart risks in adults with type II diabetes.
Zacks·11d ago
ESPR Aims to Diversify With Rare Liver Disease Candidate, Stock Up
Esperion selects ESP-2001 as a preclinical candidate for primary sclerosing cholangitis, a rare liver disease, aiming to begin clinical studies in 2026.
Zacks·15d ago
NVO and LLY Stocks Slide as Trump Signals Price Cuts for GLP-1 Drugs
Trump's pledge to slash GLP-1 drug prices sends Novo Nordisk and Eli Lilly shares tumbling, raising questions about the feasibility of such a development.
Zacks·15d ago
Viatris Acquires Aculys Pharma to Expand Neurology Portfolio in Japan
VTRS acquires Aculys Pharma to boost its CNS portfolio in Japan, gaining rights to pitolisant and Spydia for narcolepsy and seizure management, respectively.
Zacks·16d ago
CORT Files MAA for Relacorilant in Platinum-Resistant Ovarian Cancer
Corcept files a marketing application with the EMA for relacorilant in platinum-resistant ovarian cancer after studies show survival gains.